Neuphoria Therapeutics Inc Asset Resilience Ratio
Neuphoria Therapeutics Inc asset resilience ratio. Neuphoria Therapeutics Inc (NEUP) has an Asset Resilience Ratio of 0.60% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Neuphoria Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Neuphoria Therapeutics Inc (2012–2021)
Asset resilience ratio of Neuphoria Therapeutics Inc from 2012 to 2021. This chart shows how Neuphoria Therapeutics Inc's Asset Resilience Ratio has changed over time. Read NEUP current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Neuphoria Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Neuphoria Therapeutics Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $327.31K | 0.6% |
| Total Liquid Assets | $327.31K | 0.60% |
Asset Resilience Insights
- Limited Liquidity: Neuphoria Therapeutics Inc maintains only 0.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Neuphoria Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Neuphoria Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Neuphoria Therapeutics Inc Asset Resilience Ratio by Year (2012–2021)
Neuphoria Therapeutics Inc asset resilience ratio by year from 2012 to 2021. The table below shows the annual Asset Resilience Ratio data for Neuphoria Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-06-30 | 0.80% | $327.31K | $40.77 Million | -0.22pp |
| 2019-06-30 | 1.02% | $385.19K | $37.58 Million | +0.18pp |
| 2018-06-30 | 0.85% | $404.02K | $47.80 Million | +0.19pp |
| 2017-06-30 | 0.65% | $422.65K | $64.61 Million | +0.03pp |
| 2016-06-30 | 0.62% | $410.73K | $65.72 Million | -0.17pp |
| 2015-06-30 | 0.80% | $421.85K | $53.02 Million | +0.68pp |
| 2012-06-30 | 0.11% | $36.23K | $31.83 Million | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also deve… Read more